CHICAGO -- The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

Two-Part Dose Escalation and Expansion Trial Will Evaluate Efficacy and Safety of BYON4228 Alone and in Combination with Pembrolizumab NIJMEGEN, The ...

Stage 4 lymphoma is a blood cancer that has spread outside of the lymph nodes to other parts of the body. Learn the symptoms, ...

Beloved Australian actor, Magda Szubanski, has revealed she's been diagnosed with a "very rare, very aggressive, very serious ...

Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities (DLTs) ...

An international clinical trial shows an innovative CAR-T cell immunotherapy is promising against aggressive T cell cancers and has manageable side effects.

A study initiated by a University of Arizona Comprehensive Cancer Center physician-scientist defined for the first time how ...

TIM3-blockade synergizes with IL2 in alleviating intra-tumoral CD8 + T cell exhaustion Blockade of alternative T cell checkpoint molecules, such as Tim3, is a promising alternative to inhibition ...

Relevance section written by JCO Associate Editor Thomas E. Stinchcombe, MD. Tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE) molecule, binds both DLL3 on cancer cells and CD3 on ...

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...